Intra-Cellular Therapies, Inc.
ITCI
शेयरों में रैंक
#1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
शेयर मूल्य
$131.87
अंतिम समन्वयन: 2025-04-02
मार्केट कैप
$12.68B
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Intra-Cellular Therapies, Inc. (ITCI)
श्रेणी
Healthcare
Intra-Cellular Therapies, Inc. (ITCI) के लिए बकाया शेयरों की संख्या
December 2024 की स्थिति में बकाया शेयरों की संख्या: 103.13M
Intra-Cellular Therapies, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 103.13M है। December 2023 के अंत में कंपनी के पास 95.88M बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Intra-Cellular Therapies, Inc. (ITCI) के लिए 2013 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
| वर्ष | बकाया शेयर | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 103.13M | 0.00% |
| 2024 | 103.13M | 7.56% |
| 2023 | 95.88M | 1.95% |
| 2022 | 94.05M | 15.74% |
| 2021 | 81.25M | 15.47% |
| 2020 | 70.36M | 27.50% |
| 2019 | 55.19M | 0.87% |
| 2018 | 54.71M | 18.46% |
| 2017 | 46.18M | 6.80% |
| 2016 | 43.24M | 20.07% |
| 2015 | 36.01M | 25.69% |
| 2014 | 28.65M | 66.35% |
| 2013 | 17.22M | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
| कंपनी | बकाया शेयर | अंतर | देश |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 2,226.49% |
IN
|
